Completed PHASE2 NCT00148070

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Sponsor: Aventis Pharmaceuticals

Interventions Docetaxel Erythromycin Breath Test (ERMBT)

Updated 7 times since 2017 Last updated: Oct 3, 2012 Started: Mar 31, 1999 Primary completion: Sep 30, 2004 Completion: Feb 28, 2006

Listed as NCT00148070, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
Rhone-Poulenc Rorer
University of Michigan Rogel Cancer Center

Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States